Pilot Study: Repeated Utenpanium (RZL-012) Treatment for Submental Fat Reduction
Sachin M Shridharani1, Brian S Biesman2, Racheli Gueta3
1From the Aesthetic Plastic Surgery, LUXURGERY, New York, NY.
Plastic and Reconstructive Surgery. Global Open
|April 29, 2026
Summary
Repeat Utenpanium (RZL-012) injections effectively reduced submental fat (SMF) in patients seeking further aesthetic improvement. This retreatment demonstrated superior results and high patient satisfaction with a favorable safety profile.
Area of Science:
- Aesthetics
- Dermatology
- Pharmacology
Background:
- Utenpanium (RZL-012) is a novel injectable cytolytic agent.
- It is under development for aesthetic and therapeutic uses.
- This study focuses on repeat treatment for submental fat (SMF) reduction.
Purpose of the Study:
- To evaluate the safety and efficacy of repeat RZL-012 treatment for SMF reduction.
- To assess outcomes in patients previously treated with RZL-012.
- To determine patient satisfaction and safety following retreatment.
Main Methods:
- An open-label phase 2 study was conducted.
- Fifteen patients received a second RZL-012 treatment for SMF.
- Patients were followed for over 84 days, with assessments using standardized tools and safety monitoring.
Main Results:
- 100% of patients showed at least a 1-grade improvement in SMF appearance.
- 47% achieved at least a 2-grade improvement, exceeding initial treatment results.
- 80% of patients reported satisfaction with the outcomes, and adverse events were localized and consistent with prior studies.
Conclusions:
- Repeat RZL-012 treatment offers additional SMF reduction benefits.
- The retreatment shows a favorable safety and tolerability profile.
- RZL-012 is a potential option for patients seeking further aesthetic enhancement for SMF.
